Versant, RA Bet $47M on LENZ Therapeutics to Restore Near Vision in Middle Age

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Stablix, Seeking to Stabilize Instead of Degrade Proteins, Raises $63M
Versant Ventures, Sticking With its Knitting, Raises $950M for Early Stage Biotechs
What Happened in Switzerland?
RayzeBio Snags $45M to Reimagine Targeted Radiotherapies for Cancer